Intravitreal triamcinolone acetonide (IVTA) is a commonly employed treatment for various vitreoretinal disorders. However, approximately 23% to 50% of patients who receive IVTA develop ocular hypertension after the drug is injected into the eye. Similar to IVTA, topically administered corticosteroids eye drops result in ocular hypertension in approximately 33% of the population. It is unknown whether identifying patients who develop ocular hypertension from topical corticosteroids could be used to identify patients who are at risk for injectable IVTA. Therefore, the purpose of this study is to evaluate the efficacy of topical prednisolone 1% four times daily for one month as a screening test to reduce the incidence and severity of ocular hypertension after IVTA injection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
70
Prednisolone 1% 1gtt qid to the eye requiring IVTA
Hotel Dieu Hospital
Kingston, Ontario, Canada
RECRUITINGThe Ottawa Hospital
Ottawa, Ontario, Canada
NOT_YET_RECRUITINGSunnybrook Health Sciences Centre
Toronto, Ontario, Canada
RECRUITINGToronto Western Hospital
Toronto, Ontario, Canada
NOT_YET_RECRUITINGTo detect a 60% or greater decrease of developing ocular hypertension (>20 mmHg) in the group of patients who received a trial of prednisolone 1% gtts x 4 weeks, compared the group who did not receive a trial of topical prednisolone.
Time frame: Monthly for 6 months
Visual Acuity
Time frame: Monthly for 6 months
Incidence of other complications (cataract, retinal detachment, endophthalmitis)
Time frame: Monthly for 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.